In this study, we retrospectively collected and analyzed the efficacy and safety of using a PD-1 inhibitor with nab-paclitaxel in patients with advanced gastric cancer, hoping to provide substantive evidence for the a second-line treatment of advanced gastric cancer. The gene discussed is PDCD1; the disease is gastric cancer.